Myofibrillar myopathies: New developments

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 527-535

  Olivé, Montse ^a   Kley, Rudolf A ^b   Goldfarb, Lev G ^c  

^a ICS Institute of Neuropathology   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA CRYSTALLIN; AMYLOID BETA PROTEIN; BCL 2 ASSOCIATED ATHANOGENE 3; CRYSTALLIN; CYTOSKELETON PROTEIN; DESMIN; FILAMIN; FILAMIN C; MYOTILIN; PROTEIN; UNCLASSIFIED DRUG; Z BAND ALTERNATIVELY SPLICED PDZ CONTAINING PROTEIN;

AMYLOID BETA CRYSTALLINOPATHY; BAG3 MYOPATHY; DESMINOPATHY; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MASS SPECTROMETRY; MEDICAL TECHNOLOGY; MFM FILAMINOPATHY; MOLECULAR DIAGNOSIS; MYOFIBRILLAR MYOPATHY; MYOPATHY; MYOTILINOPATHY; NONHUMAN; PHENOTYPE; PROTEOMICS; RESPIRATORY FAILURE; REVIEW; ULTRASTRUCTURE; ZASPOPATHY;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUTATION; MYOPATHIES, STRUCTURAL, CONGENITAL; PHENOTYPE;

EID: 84883762522     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364d6b1     Document Type: Review

References (78)

1. Nakano S, Engel AG, Waclawik AJ, et al. Myofibrillar myopathy with abnormal foci of desmin positivity. 1. Light and electron microscopy analysis of 10 cases. J Neuropathol Exp Neurol 1996; 55:549-562.
2. Selcen D. Myofibrillar myopathies. Neuromuscul Disord 2011; 21:161-171.
3. Goebel HH. Protein aggregate myopathies. Introduction. Brain Pathol 2009; 19:480-482.
4. Goebel HH, Blaschek A. Protein aggregation in congenital myopathies. Semin Pediatr Neurol 2011; 18:272-276.
5. Selcen D, Engel AG. Myofibrillar myopathy. In: Pagon RA, Bird TD, Dolan CR, et al., editors. GeneReviewsTM [Internet]. Seattle, WA: University of Washington; 1993-2003.
6. Ferrer I, Olivé M. Molecular pathology of myofibrillar myopathies. Expert Rev Mol Med 2008; 10:e25.
7. Schrö der R, Schoser B. Myofibrillar myopathies: A clinical and myopathological guide. Brain Pathol 2009; 19:483-492.
8. BrookeMH, Neville HE. Reducing body myopathy. Neurology 1972; 22:829-840.
9. Schessl J, Zou Y, McGrath MJ, et al. Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy. J Clin Invest 2008; 118:904-912.
10. Schessl J, Taratuto AL, Sewry C, et al. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.
11. Figarella-Branger D, Putzu GA, Bouvier-Labit C, et al. Adult onset reducing body myopathy. Neuromuscul Disord 1999; 9:580-586.
12. Schessl J, Feldkirchner S, Kubny C, Schoser B. Reducing body myopathy and other FHL1-related muscular disorders. Semin Pediatr Neurol 2011; 18:257-263.
13. Cowling BS, Cottle DL, Wilding BR, et al. Four and a half LIM protein 1 gene mutations cause four distinct human myopathies: A comprehensive review of the clinical, histological and pathological features. Neuromuscul Disord 2011; 21:237-251.
14. Windpassinger C, Schoser B, Straub V, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet 2008; 82:88-99.
15. Quinzii CM, Vu TH, Min KC, et al. X-linked dominant scapuloperoneal myopathy is due to a mutation in the gene encoding four-and-a-half-LIM protein 1. Am J Hum Genet 2008; 82:208-213.
16. Shalaby S, Hayashi YK, Goto K, et al. I. Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1). Neuromuscul Disord 2008; 18:959-961.
17. Gueneau L, Bertrand AT, Jais JP, et al. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2009; 85:338-353.
18. Friedrich FW, Wilding BR, Reischmann S, et al. Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet 2012; 21:3237-3254.
19. Feldkirchner S, Walter MC, Müller S, et al. Proteomic characterization of aggregate components in an intrafamilial variable FHL1-associated myopathy. Neuromuscul Disord 2013; 23:418-426.
20. Goebel HH, Halbig LE, Goldfarb L, et al. Reducing body myopathy with cytoplasmic bodies and rigid spine syndrome: A mixed congenital myopathy. Neuropediatrics 2001; 32:196-205.
21. Selcen D, Bromberg MB, Chin SS, Engel AG. Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy. Neurology 1951; 77:9.
22. Schreckenbach T, Henn W, Kress W, et al. Novel FHL1 mutation in a family with reducing body myopathy. Muscle Nerve 2013; 47:127-134.
23. Edström L, Thornell LE, Albo J, et al. Myopathy with respiratory failure and typical myofibrillar lesions. J Neurol Sci 1990; 96:211-228.
24. Lange S, Xiang F, Yakovenko A, et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005; 308:1599-1603.
25. Ohlsson M, Hedberg C, Brädvik B, et al. Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. Brain 2012; 135:1682-1694.
26. Pfeffer G, Elliott HR, Griffin H, et al. Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain 2012; 135:1695-1713.
27. Pfeffer G, Barresi R, Wilson IJ, et al. Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure. J Neurol Neurosurg Psychiatry 2013. [Epub ahead of print]
28. Izumi R, Niihori T, Aoki Y, et al. Exome sequencing identifies a novel TTN mutation in a family with hereditary myopathy with early respiratory failure. J Hum Genet 2013; 58:259-266.
29. Toro C, Olivé M, Dalakas M, et al. Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure in families of diverse ethnic origins. BMC Neurology 2013; 13:29-43.
30. Palmio J, Evilä A, Chapon F, et al. Hereditary myopathy with early respiratory failure: Occurrence in various populations. J Neurol Neurosurg Psychiatry 2013. [Epub ahead of print]
31. Feldkirchner S, Schessl J, Müller S, et al. Patient-specific protein aggregates in myofibrillar myopathies: Laser microdissection and differential proteomics for identification of plaque components. Proteomics 2012; 12:3598-3609.
32. KleyRA,Maerkens A, Leber Y, et al.Acombined laser microdissection andmass spectrometry approach reveals new disease relevant proteins accumulating in aggregates of filaminopathy patients. Mol Cell Proteomics 2013; 12:215-227.
33. Maerkens A, Kley RA, Olivé M, et al. Differential proteomic analysis of abnormal intramyoplasmic aggregates in desminopathy. J Proteomics 2013; doi:10.1016/j.prot.2013.04.026. [Epub ahead of print]
34. Goldfarb LG, Park KY, Cervenakova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nat Genet 1998; 19:402-403.
35. Muñoz-Mármol AM, Strasser G, Isamat M, et al. A dysfunctional desmin mutation in a patient with severe generalizad myopathy. Proc Natl Acad Sci U S A 1998; 95:11312-11317.
36. Goldfarb LG, Olivé M, Vicart P, Goebel HH. Intermediate filament diseases: Desminopathy. Adv Exp Med Biol 2008; 642:131-164.
37. Clemen CS, Herrmann H, Strelkov SV, Schrö der R. Desminopathies: Pathology and mechanisms. Acta Neuropathol 2013; 125:47-75.
38. van Spaendonck-Zwarts KY, van der Kooi AJ, van den Berg MP, et al. Recurrent and founder mutations in the Netherlands: The cardiac phenotype of DES founder mutations p.S13F and p N342D. Neth Heart J 2012; 20:219-228.
39. Wahbi K, Bé hin A, Charron P, et al. High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: A 10-year longitudinal study. Neuromuscul Disord 2012; 22:211-218.
40. Klauke B, Kossmann S, Gaertner A, et al. De novo desmin-mutation N116S is associated with arrhythmogenic right ventricular cardiomyopathy. Hum Mol Genet 2010; 19:4595-4607.
41. Hedberg C, Melberg A, Kuhl A, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy 7 is caused by a DES mutation. Eur J Hum Genet 2012; 20:984-985.
42. Melberg A, Oldfors A, Blomströ m-Lundqvist C, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol 1999; 46:684-692.
43. Henderson M, De Waele L, Hudson J, et al. Recessive desmin-null muscular dystrophy with central nuclei and mitochondrial abnormalities. Acta Neurpathol 2013; 125:917-919.
44. Greenberg SA, Salajegheh M, Judge DP, et al. Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Ann Neurol 2012; 71:141-145.
45. Bonakdar N, Luczak J, Lautscham L, et al. Biomechanical characterization of a desminopathy in primary human myoblasts. Biochem Biophys Res Commun 2012; 419:703-707.
46. Joanne P, Chourbagi O, Hourdé C, et al. Viral-mediated expression of desmin mutants to create mouse models of myofibrillar myopathy. Skelet Muscle 2013; 3:4.
47. Vicart P, Caron A, Guicheney P, et al. A missense mutation in the alphaBcrystallin chaperone gene causes a desmin-related myopathy. Nature Genet 1998; 20:92-95.
48. Fardeau M, Godet-Guillain J, Tomé FM, et al. Une nouvelle affection musculaire familiale, definie par l'accumulation intra-sarco-plasmique d'un materiel granulo-filamentaire dense en microscopie electronique. Rev Neurol 1978; 134:411-425.
49. Sacconi S, Fé asson L, Antoine JC, et al. A novel CRYAB mutation resulting in multisystemic disease. Neuromuscul Disord 2012; 22:66-72.
50. Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann Neurol 2003; 54:804-810.
51. Reilich P, Schoser B, Schramm N, et al. The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. Neuromuscul Disord 2010; 20:255-259.
52. Andley UP, Hamilton PD, Ravi N, Weihl CC. A knock-in mouse model for the R120G mutation of aB-crystallin recapitulates human hereditary myopathy and cataracts. PLoS One 2011; 6:e17671.
53. Forrest KM, Al-Sarraj S, Sewry C, et al. Infantile onset myofibrillar myopathy due to recessive CRYAB mutations. Neuromuscul Disord 2011; 21:37-40.
54. Del Bigio MR, Chudley AE, Sarnat HB, et al. Infantile muscular dystrophy in Canadian aboriginals is an aB-crystallinopathy. Ann Neurol 2011; 69:866-871.
55. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1 A. Hum Mol Genet 2000; 14:2141-2147.
56. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. Neurology 2004; 62:1363-1371.
57. Olivé M, Goldfarb L, Shatunov A, et al. Myotilinopathy: Refining the clinical and myopathological phenotype. Brain 2005; 128:2315-2326.
58. Shalaby S, Mitsuhashi H, Matsuda C, et al. Defective myotilin homodimerization caused by a novel mutation in MYOT exon 9 in the first Japanese limb girdle muscular dystrophy 1A patient. J Neuropathol Exp Neurol 2009; 68:701-707.
59. von Nandelstadh P, Soliymani R, Baumann M, Carpen O. Analysis of myotilin turnover provides mechanistic insight into the role of myotilinopathy-causing mutations. Biochem J 2011; 436:113-121.
60. Ferrer I, Martín B, Castaño JG, et al. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004; 63:484-498.
61. Kley RA, Serdaroglu-Oflazer P, Leber Y, et al. Pathophysiology of protein aggregation and extended phenotyping in filaminopathy. Brain 2012; 135:2642-2660.
62. Keduka E, Hayashi YK, Shalaby S, et al. In vivo characterization of mutant myotilins. Am J Pathol 2012; 180:1570-1580.
63. Selcen D, Engel AG. Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann Neurol 2005; 57:269-276.
64. Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain 2007; 130:1477-1484.
65. Strach K, Reimann J, Thomas D, et al. ZASPopathy with childhood-onset distal myopathy. J Neurol 2012; 259:1494-1496.
66. Cai H, Yabe I, Sato K, et al. H. Clinical, pathological, and genetic mutation analysis of sporadic inclusion body myositis in Japanese people. J Neurol 2012; 259:1913-1922.
67. Vorgerd M, van der Ven PF, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet 2005; 77:297-304.
68. Fürst DO, Goldfarb LG, Kley RA, et al. Filamin C-related myopathies: Pathology and mechanisms. Acta Neuropathol 2013; 125:33-46.
69. Tasca G, Odgerel Z, Monforte M, et al. Novel FLNC mutation in a patient with myofibrillar myopathy in combination with late-onset cerebellar ataxia. Muscle Nerve 2012; 46:275-282.
70. Ruparelia AA, Zhao M, Currie PD, Bryson-Richardson RJ. Characterization and investigation of zebrafish models of filamin-related myofibrillar myopathy. Hum Mol Genet 2012; 21:4073-4083.
71. Fujita M, Mitsuhashi H, Isogai S, et al. Filamin C plays an essential role in the maintenance of the structural integrity of cardiac and skeletal muscles, revealed by the medaka mutant zacro. Dev Biol 2012; 361:79-89.
72. Selcen D, Muntoni F, Burton BK, et al. Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol 2009; 65:83-89.
73. Odgerel Z, Sarkozy A, Lee HS, et al. Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation. Neuromuscul Disord 2010; 20:438-442.
74. Lee HC, Cherk SW, Chan SK, et al. BAG3-related myofibrillar myopathy in a Chinese family. Clin Genet 2012; 81:394-398.
75. Jaffer F, Murphy SM, Scoto M, et al. BAG3 mutations: Another cause of giant axonal neuropathy. J Peripher Nerv Syst 2012; 17:210-216.
76. Claeys KG, Fardeau M, Schrö der R, et al. Electron microscopy in myofibrillar myopathies reveal clues to the mutated gene. Neuromuscul Disord 2008; 18:656-666.
77. Olivé M, Odgerel Z, Martínez A, et al. Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul Disord 2011; 21:533-542.
78. Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 2008; 71:758-765.